NIH cancer study on Nexrutine
This article was originally published in The Tan Sheet
Executive Summary
NIH's National Center for Complementary & Alternative Medicine awards two-year grant to AMC Cancer Research Center to study Next Pharmaceuticals' Nexrutine anti-inflammatory dietary supplement ingredient as a prostate cancer preventive agent, the Denver Colo.-based research institute announces Sept. 16. Nexrutine is a plant extract from bark of Phellodendron trees commonly found in Asia. AMC plans to determine the molecular mechanism underlying the ingredient's efficacy. Previous studies by Dr. Pratap Kumar, the proposal's principal investigator, found Nexrutine inhibits prostate cancer cell growth...